ATRX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ATRX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Adhera Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $10.83 Mil. Adhera Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.00 Mil. Adhera Therapeutics's Total Stockholders Equity for the quarter that ended in Sep. 2023 was $-26.32 Mil. Adhera Therapeutics's debt to equity for the quarter that ended in Sep. 2023 was -0.41.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Adhera Therapeutics's Debt-to-Equity or its related term are showing as below:
During the past 13 years, the highest Debt-to-Equity Ratio of Adhera Therapeutics was 4.25. The lowest was -2.58. And the median was -0.37.
The historical data trend for Adhera Therapeutics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adhera Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | |||||||||||
Debt-to-Equity | Get a 7-Day Free Trial | - | -0.54 | -0.43 | -0.27 | -0.39 |
Adhera Therapeutics Quarterly Data | ||||||||||||||||||||
Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | |
Debt-to-Equity | Get a 7-Day Free Trial | -0.37 | -0.39 | -0.42 | -0.47 | -0.41 |
For the Biotechnology subindustry, Adhera Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Adhera Therapeutics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Adhera Therapeutics's Debt-to-Equity falls into.
Debt to Equity measures the financial leverage a company has.
Adhera Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as
Debt to Equity | = | Total Debt | / | Total Stockholders Equity | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Total Stockholders Equity | |
= | (8.585 | + | 0) | / | -22.186 | |
= | -0.39 |
Adhera Therapeutics's Debt to Equity Ratio for the quarter that ended in Sep. 2023 is calculated as
Debt to Equity | = | Total Debt | / | Total Stockholders Equity | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Total Stockholders Equity | |
= | (10.829 | + | 0) | / | -26.315 | |
= | -0.41 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adhera Therapeutics (OTCPK:ATRX) Debt-to-Equity Explanation
In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.
Be Aware
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Thank you for viewing the detailed overview of Adhera Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.
Zahed Subhan | director | 8000 INNOVATION PARKWAY, BATON ROUGE LA 70820 |
Trond Kydd Waerness | director | 8000 INNOVATION PARKWAY, BAON ROUGE LA 70820 |
Rice Charles L Jr | director | C/O ENTERGY CORPORATION LEGAL DEPT., 639 LOYOLA AVE., 26TH FLOOR, NEW ORLEANS LA 70113 |
Andrew Albert Kucharchuk | director, officer: Chief Executive Officer | 549 MILGATE PLACE, BATON ROUGE LA 70810 |
Rhonda L. Stanley | officer: SVP Finance & Accounting | 5001 SOUTH MIAMA BOULEVARD, SUITE 300, DURHAM NC 27703 |
Nancy R. Phelan | director | 812 MAPLEWOOD ROAD, WAYNE PA 19087 |
Robert Eric Teague | officer: Chief Financial Officer | C/O MARINA BIOTECH, INC., 4721 EMPEROR BOULEVARD, SUITE 350, DURHAM NC 27703 |
Uli Hacksell | director | 3911 SORRENTO VALLEY BOULEVARD, SAN DIEGO CA 92121 |
Robert Jr. Moscato | officer: CEO | 400 PRATT STREET, SUITE 606, BALTIMORE MD 21202 |
Timothy Boris | director | 805 AEROVISTA PLACE, SUITE 205, SAN LUIS OBISPO CA 93401 |
Isaac Blech | director | C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116 |
Peter D. Weinstein | officer: Chief Legal Officer | C.O MARINA BIOTECH, INC., 17870 CASTLETON STREET, SUITE 250, CITY OF INDUSTRY CA 91748 |
Amit B. Shah | officer: Chief Financial Officer | 10 AGUILA, ALISO VIEJO CA 92656 |
Erik C. Emerson | officer: Chief Commercial Officer | 2300 WEST SAHARA AVENUE, SUITE 800 - #4012, LAS VEGAS NV 89102 |
Mihir Munsif | officer: Chief Operating Officer | 21102 BRIARWOOD LANE, TRABUCO CANYON CA 92679 |
From GuruFocus
By [email protected] [email protected] • 09-10-2019
By Marketwired Marketwired • 10-03-2018
By ACCESSWIRE AccessWire • 04-12-2019
By PurpleRose PurpleRose • 07-19-2022
By GuruFocusNews GuruFocusNews • 06-28-2022
By GuruFocusNews GuruFocusNews • 06-08-2022
By gurufocus 10qk • 05-17-2010
By gurufocus 10qk • 11-12-2009
By GuruFocusNews GuruFocusNews • 05-29-2022
By GlobeNewswire GlobeNewswire • 11-21-2018
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.